2013
Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJ. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Research And Treatment 2013, 141: 421-427. PMID: 24062210, DOI: 10.1007/s10549-013-2700-1.Peer-Reviewed Original ResearchConceptsEndoxifen levelsEndocrine therapyBreast cancerCYP2D6 genotypeAdjuvant tamoxifenTamoxifen metabolismOptimal adjuvant endocrine therapyAlternative endocrine therapyBaseline whole bloodAdjuvant endocrine therapyMedical record reviewActual treatment decisionsPoor metabolizer genotypeCytochrome P450 2D6Record reviewClinical evidenceTreatment recommendationsTherapy recommendationsTreatment decisionsEstrogen receptorHormonal treatmentStage IClinical practicePatientsTamoxifen
2006
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC, _ _. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. Journal Of The National Comprehensive Cancer Network 2006, 4 Suppl 1: s1-26. PMID: 16507275, DOI: 10.6004/jnccn.2006.2001.Peer-Reviewed Original ResearchConceptsNational Comprehensive Cancer NetworkBreast cancer treatment guidelinesCancer treatment guidelinesAdjuvant therapyBreast cancerTreatment guidelinesAdjuvant therapy recommendationsQuantitative estrogen receptorComprehensive Cancer NetworkEstrogen receptor levelsPositive breast cancerEndocrine therapyPostmenopausal womenMenopausal statusTask ForcePredictive factorsGuideline panelHER2 statusBiologic markersAromatase inhibitorsTherapy recommendationsReceptor levelsEstrogen receptorHER2/Cancer Network